MetaCap

MBX Biosciences (MBX) vs Xencor (XNCR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xencor (XNCR) has outperformed MBX Biosciences (MBX) over the past year, gaining 109.6% versus a gain of 83.0%. Xencor is the larger company by market cap ($2.50 billion vs $2.46 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MBX+82.98%XNCR+109.58%
+171%+63%-44%
Nov 21, 20251 yearNov 20, 2026
MBX+109.51%XNCR+54.91%
+203%+58%-88%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MBX versus XNCR key metrics
MetricMBXXNCR
Share price$49.55$33.26
Market cap$2.46B$2.50B
1-day change-7.23%-2.21%
YTD return+57.10%+117.24%
1-year return+82.98%+109.58%
5-year return—-6.15%
EPS (TTM)$-3.03$-1.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$125.58M
Revenue growth (YoY)—+13.65%
Net income (latest FY)$-87.00M$-91.92M
Operating margin—-141.35%
Net margin—-73.20%
52-week high$72.64$40.60
52-week low$26.14$10.38
Distance from 52-week high-31.79%-18.08%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+91.91%+27.78%
Average volume532.80K1.54M
Shares outstanding49.66M75.04M
Employees63260
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XNCR has outperformed MBX by 26.6 percentage points over the past year.

About MBX Biosciences

MBX stock →

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

About Xencor

XNCR stock →

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

MBX vs XNCR FAQ

Which is bigger, MBX Biosciences or Xencor?

Xencor (XNCR) is larger, with a market capitalization of $2.50B compared with $2.46B for MBX Biosciences (MBX).

Which stock has performed better over the past year, MBX or XNCR?

XNCR returned +109.58% over the past 12 months, compared with +82.98% for MBX (price return, excluding dividends). Past performance does not predict future results.

Are MBX Biosciences and Xencor in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons